Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

Gene expression changes associated with chemotherapy resistance in Ewing sarcoma cells.

Horbach L, Sinigaglia M, Da Silva CA, Olguins DB, Gregianin LJ, Brunetto AL, Brunetto AT, Roesler R, De Farias CB.

Mol Clin Oncol. 2018 Jun;8(6):719-724. doi: 10.3892/mco.2018.1608. Epub 2018 Apr 13.

2.

Targeting Histone Deacetylase Activity to Arrest Cell Growth and Promote Neural Differentiation in Ewing Sarcoma.

Souza BK, da Costa Lopez PL, Menegotto PR, Vieira IA, Kersting N, Abujamra AL, Brunetto AT, Brunetto AL, Gregianin L, de Farias CB, Thiele CJ, Roesler R.

Mol Neurobiol. 2018 Sep;55(9):7242-7258. doi: 10.1007/s12035-018-0874-6. Epub 2018 Feb 3.

PMID:
29397557
3.

What is the impact of local control in Ewing sarcoma: analysis of the first Brazilian collaborative study group - EWING1.

Becker RG, Gregianin LJ, Galia CR, Jesus-Garcia Filho R, Toller EA, Badell G, Nakagawa SA, David A, Baptista AM, Yonamime ES, Serafini OA, Penna V, Santos JFC, Brunetto AL; Brazilian Collaborative Study Group of Ewing Family of Tumors – EWING1 and the Brazilian Society of Pediatric Oncology – SOBOPE.

BMC Cancer. 2017 Jun 15;17(1):420. doi: 10.1186/s12885-017-3391-5.

4.

Results of a randomized, prospective clinical trial evaluating metronomic chemotherapy in nonmetastatic patients with high-grade, operable osteosarcomas of the extremities: A report from the Latin American Group of Osteosarcoma Treatment.

Senerchia AA, Macedo CR, Ferman S, Scopinaro M, Cacciavillano W, Boldrini E, Lins de Moraes VL, Rey G, de Oliveira CT, Castillo L, Almeida MT, Borsato ML, Lima E, Lustosa D, Barreto JH, El-Jaick T, Aguiar S, Brunetto A, Greggiani L, Cogo-Moreira H, Atallah A, Petrilli AS.

Cancer. 2017 May 15;123(6):1003-1010. doi: 10.1002/cncr.30411. Epub 2016 Nov 7. Erratum in: Cancer. 2018 Apr 1;124(7):1518.

5.

DNA damage response in patients with pediatric Acute Lymphoid Leukemia during induction therapy.

Portich JP, Dos Santos RP, Kersting N, Jorge KB, Casagrande PR, Dos Santos Costa G, Dias Cionek JM, Olguins DB, Sinigaglia M, Busatto FF, Saffi J, Maluf SW, Loss JF, Brunetto AL, Roesler R, de Farias CB.

Leuk Res. 2017 Mar;54:59-65. doi: 10.1016/j.leukres.2017.01.013. Epub 2017 Jan 11.

PMID:
28109975
6.

Combined Treatments with a Retinoid Receptor Agonist and Epigenetic Modulators in Human Neuroblastoma Cells.

Almeida VR, Vieira IA, Buendia M, Brunetto AT, Gregianin LJ, Brunetto AL, Klamt F, de Farias CB, Abujamra AL, Lopez PLDC, Roesler R.

Mol Neurobiol. 2017 Dec;54(10):7610-7619. doi: 10.1007/s12035-016-0250-3. Epub 2016 Nov 10.

PMID:
27832522
7.

Low brain-derived neurotrophic factor levels are associated with active disease and poor prognosis in childhood acute leukemia.

Portich JP, Gil MS, Dos Santos RP, Goulart BK, Ferreira MB, Loss JF, Gregianin LJ, Brunetto AL, Brunetto AT, Roesler R, de Farias CB.

Cancer Biomark. 2016 Sep 26;17(3):347-352.

PMID:
27434294
8.

Trk inhibition reduces cell proliferation and potentiates the effects of chemotherapeutic agents in Ewing sarcoma.

Heinen TE, Dos Santos RP, da Rocha A, Dos Santos MP, Lopez PL, Silva Filho MA, Souza BK, Rivero LF, Becker RG, Gregianin LJ, Brunetto AL, Brunetto AT, de Farias CB, Roesler R.

Oncotarget. 2016 Jun 7;7(23):34860-80. doi: 10.18632/oncotarget.8992.

9.

BDNF/TrkB Signaling as a Potential Novel Target in Pediatric Brain Tumors: Anticancer Activity of Selective TrkB Inhibition in Medulloblastoma Cells.

Thomaz A, Jaeger M, Buendia M, Bambini-Junior V, Gregianin LJ, Brunetto AL, Brunetto AT, de Farias CB, Roesler R.

J Mol Neurosci. 2016 Jul;59(3):326-33. doi: 10.1007/s12031-015-0689-0. Epub 2015 Nov 27.

PMID:
26614346
10.

Viability of D283 medulloblastoma cells treated with a histone deacetylase inhibitor combined with bombesin receptor antagonists.

Jaeger M, Ghisleni EC, Fratini L, Brunetto AL, Gregianin LJ, Brunetto AT, Schwartsmann G, de Farias CB, Roesler R.

Childs Nerv Syst. 2016 Jan;32(1):61-4. doi: 10.1007/s00381-015-2963-4. Epub 2015 Nov 20.

PMID:
26590027
11.

Carboplatin in the treatment of Ewing sarcoma: Results of the first Brazilian collaborative study group for Ewing sarcoma family tumors-EWING1.

Brunetto AL, Castillo LA, Petrilli AS, Macedo CD, Boldrini E, Costa C, Almeida MT, Kirst D, Rodriguez-Galindo C, Pereira WV, Watanabe FM, Pizza M, Benites E, Morais V, Gadelha A, Nakasato A, Abujamra AL, Gregianin LJ; Brazilian Collaborative On behalf of the Brazilian Collaborative Study Group of Ewing Family of Tumors EWING1 and the Brazilian Society of Pediatric Oncology SOBOPE.

Pediatr Blood Cancer. 2015 Oct;62(10):1747-53. doi: 10.1002/pbc.25562. Epub 2015 Apr 27.

PMID:
25917418
12.

Osteosarcoma in patients younger than 12 years old without metastases have similar prognosis as adolescent and young adults.

Eleutério SJ, Senerchia AA, Almeida MT, Da Costa CM, Lustosa D, Calheiros LM, Barreto JH, Brunetto AL, Macedo CR, Petrilli AS.

Pediatr Blood Cancer. 2015 Jul;62(7):1209-13. doi: 10.1002/pbc.25459. Epub 2015 Mar 8.

PMID:
25755160
13.

Orthodontic retreatment of a Class III patient with significant midline asymmetry and bilateral posterior crossbite.

Brunetto AR.

Dental Press J Orthod. 2015 Jan-Feb;20(1):118-26. doi: 10.1590/2176-9451.20.1.118-126.bbo.

14.

A phase I, dose-escalation study of the multitargeted receptor tyrosine kinase inhibitor, golvatinib, in patients with advanced solid tumors.

Molife LR, Dean EJ, Blanco-Codesido M, Krebs MG, Brunetto AT, Greystoke AP, Daniele G, Lee L, Kuznetsov G, Myint KT, Wood K, de Las Heras B, Ranson MR.

Clin Cancer Res. 2014 Dec 15;20(24):6284-94. doi: 10.1158/1078-0432.CCR-14-0409. Epub 2014 Oct 2.

15.

Dose-response relationship in phase i clinical trials: a European Drug Development Network (EDDN) Collaboration Study.

Moreno García V, Olmos D, Gomez-Roca C, Cassier PA, Morales-Barrera R, Del Conte G, Gallerani E, Brunetto AT, Schöffski P, Marsoni S, Schellens JH, Penel N, Voest E, Evans J, Plummer R, Wilson RH, Soria JC, Tabernero J, Verweij J, Kaye SB.

Clin Cancer Res. 2014 Nov 15;20(22):5663-71. doi: 10.1158/1078-0432.CCR-14-0719. Epub 2014 Sep 24.

16.

Inhibitory activities of trichostatin a in U87 glioblastoma cells and tumorsphere-derived cells.

Sassi Fde A, Caesar L, Jaeger M, Nör C, Abujamra AL, Schwartsmann G, de Farias CB, Brunetto AL, Lopez PL, Roesler R.

J Mol Neurosci. 2014 Sep;54(1):27-40. doi: 10.1007/s12031-014-0241-7. Epub 2014 Jan 25.

PMID:
24464841
17.

Gastrin-releasing peptide receptor expression in lung cancer.

Mattei J, Achcar RD, Cano CH, Macedo BR, Meurer L, Batlle BS, Groshong SD, Kulczynski JM, Roesler R, Dal Lago L, Brunetto AT, Schwartsmann G.

Arch Pathol Lab Med. 2014 Jan;138(1):98-104. doi: 10.5858/arpa.2012-0679-OA.

PMID:
24377816
18.

In vitro antitumor effect of sodium butyrate and zoledronic acid combined with traditional chemotherapeutic drugs: a paradigm of synergistic molecular targeting in the treatment of Ewing sarcoma.

Dos Santos MP, de Farias CB, Roesler R, Brunetto AL, Abujamra AL.

Oncol Rep. 2014 Feb;31(2):955-68. doi: 10.3892/or.2013.2907. Epub 2013 Dec 6.

PMID:
24316794
19.

Fifteen Years' Experience of the Brazilian Osteosarcoma Treatment Group (BOTG): A Contribution from an Emerging Country.

Petrilli AS, Brunetto AL, Cypriano Mdos S, Ferraro AA, Donato Macedo CR, Senerchia AA, Almeida MT, Costa CM, Lustosa D, Borsato ML, Calheiros LM, Barreto JH, Epelman S, Carvalho E, Alves MT, Petrilli Mde T, Penna V, Pericles P, de Camargo OP, Garcia-Filho On Behalf Of The Brazilian Osteosarcoma Treatment Group RJ.

J Adolesc Young Adult Oncol. 2013 Dec;2(4):145-52. doi: 10.1089/jayao.2013.0012.

PMID:
26812261
20.

Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.

Giacomazzi J, Selistre SG, Rossi C, Alemar B, Santos-Silva P, Pereira FS, Netto CB, Cossio SL, Roth DE, Brunetto AL, Zagonel-Oliveira M, Martel-Planche G, Goldim JR, Hainaut P, Camey SA, Ashton-Prolla P.

Cancer. 2013 Dec 15;119(24):4341-9. doi: 10.1002/cncr.28346. Epub 2013 Oct 7.

21.

Neutrality of miniSTR D22S1045 marker by Ewing's sarcoma phenotype.

Silva DS, Raimann PE, Moro T, Picanço JB, Abujamra AL, de Farias CB, Roesler R, Brunetto AL, Alho CS.

Leg Med (Tokyo). 2013 Nov;15(6):335-7. doi: 10.1016/j.legalmed.2013.08.004. Epub 2013 Sep 10.

PMID:
24112992
22.

Anti-EGFR therapy combined with neuromedin B receptor blockade induces the death of DAOY medulloblastoma cells.

Jaeger M, Nör C, de Farias CB, Abujamra AL, Schwartsmann G, Brunetto AL, Roesler R.

Childs Nerv Syst. 2013 Dec;29(12):2145-50. doi: 10.1007/s00381-013-2290-6. Epub 2013 Oct 3.

PMID:
24092425
23.

First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors.

Brunetto AT, Ang JE, Lal R, Olmos D, Molife LR, Kristeleit R, Parker A, Casamayor I, Olaleye M, Mais A, Hauns B, Strobel V, Hentsch B, de Bono JS.

Clin Cancer Res. 2013 Oct 1;19(19):5494-504. doi: 10.1158/1078-0432.CCR-13-0735. Epub 2013 Sep 24.

24.

Autologous stem cell transplantation as first line treatment after incomplete excision of pancreatoblastoma.

Meneses CF, Osório CD, de Castro Junior CG, Brunetto AL.

Rev Bras Hematol Hemoter. 2013;35(2):148-9. doi: 10.5581/1516-8484.20130038.

25.

Ewing Sarcoma: influence of TP53 Arg72Pro and MDM2 T309G SNPs.

Thurow HS, Hartwig FP, Alho CS, Silva DS, Roesler R, Abujamra AL, de Farias CB, Brunetto AL, Horta BL, Dellagostin OA, Collares T, Seixas FK.

Mol Biol Rep. 2013 Aug;40(8):4929-34. doi: 10.1007/s11033-013-2593-4. Epub 2013 May 10.

PMID:
23661019
26.

The histone deacetylase inhibitor sodium butyrate promotes cell death and differentiation and reduces neurosphere formation in human medulloblastoma cells.

Nör C, Sassi FA, de Farias CB, Schwartsmann G, Abujamra AL, Lenz G, Brunetto AL, Roesler R.

Mol Neurobiol. 2013 Dec;48(3):533-43. doi: 10.1007/s12035-013-8441-7. Epub 2013 Mar 21.

PMID:
23516101
27.

Nutritional status of adolescents with hematological malignancies, bone tumors, and other solid tumors during the first year after diagnosis.

Dalle Molle R, da Cruz LB, Gregianin LJ, Brunetto AL.

Pediatr Blood Cancer. 2013 Jan;60(1):165. doi: 10.1002/pbc.24306. Epub 2012 Sep 21. No abstract available.

PMID:
23002025
28.

Ewing's sarcoma: analysis of single nucleotide polymorphism in the EWS gene.

Silva DS, Sawitzki FR, De Toni EC, Graebin P, Picanco JB, Abujamra AL, de Farias CB, Roesler R, Brunetto AL, Alho CS.

Gene. 2012 Nov 10;509(2):263-6. doi: 10.1016/j.gene.2012.08.012. Epub 2012 Aug 20.

29.

Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review.

dos Santos LV, Souza FH, Brunetto AT, Sasse AD, da Silveira Nogueira Lima JP.

J Natl Cancer Inst. 2012 Sep 5;104(17):1280-92. doi: 10.1093/jnci/djs335. Epub 2012 Aug 21. Review.

PMID:
22911671
30.

Advanced solid tumors treated with cediranib: comparison of dynamic contrast-enhanced MR imaging and CT as markers of vascular activity.

Messiou C, Orton M, Ang JE, Collins DJ, Morgan VA, Mears D, Castellano I, Papadatos-Pastos D, Brunetto A, Tunariu N, Mann H, Tessier J, Young H, Ghiorghiu D, Marley S, Kaye SB, deBono JS, Leach MO, deSouza NM.

Radiology. 2012 Nov;265(2):426-36. doi: 10.1148/radiol.12112565. Epub 2012 Aug 13.

PMID:
22891356
31.

The use of high-frequency audiometry increases the diagnosis of asymptomatic hearing loss in pediatric patients treated with cisplatin-based chemotherapy.

Abujamra AL, Escosteguy JR, Dall'Igna C, Manica D, Cigana LF, Coradini P, Brunetto A, Gregianin LJ.

Pediatr Blood Cancer. 2013 Mar;60(3):474-8. doi: 10.1002/pbc.24236. Epub 2012 Jun 28.

PMID:
22744939
32.

Diurnal variations in the parameters of pulmonary function and respiratory muscle strength in patients with COPD.

Fregonezi G, Resqueti VR, Cury JL, Paulin E, Brunetto AF.

J Bras Pneumol. 2012 Mar-Apr;38(2):257-63. English, Portuguese.

33.

Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors.

Olmos D, A'hern RP, Marsoni S, Morales R, Gomez-Roca C, Verweij J, Voest EE, Schöffski P, Ang JE, Penel N, Schellens JH, Del Conte G, Brunetto AT, Evans TR, Wilson R, Gallerani E, Plummer R, Tabernero J, Soria JC, Kaye SB.

J Clin Oncol. 2012 Mar 20;30(9):996-1004. doi: 10.1200/JCO.2010.34.5074. Epub 2012 Feb 21.

PMID:
22355064
34.

BDNF/TrkB signaling as an anti-tumor target.

Roesler R, de Farias CB, Abujamra AL, Brunetto AL, Schwartsmann G.

Expert Rev Anticancer Ther. 2011 Oct;11(10):1473-5. doi: 10.1586/era.11.150. No abstract available.

PMID:
21999118
35.

Perceptions and referral trends into phase I oncology trials: results of a clinical survey.

Brunetto A, Olmos D, Arkenau HT, Tan D, Yap T, de Bono J, Barriuso J, Kaye S.

J Oncol. 2011;2011:861401. doi: 10.1155/2011/861401. Epub 2011 Jun 27.

36.

Survivin as a predictive biomarker of complete pathologic response to neoadjuvant chemotherapy in patients with stage II and stage III breast cancer.

Petrarca CR, Brunetto AT, Duval V, Brondani A, Carvalho GP, Garicochea B.

Clin Breast Cancer. 2011 Apr;11(2):129-34. doi: 10.1016/j.clbc.2011.03.002. Epub 2011 Apr 11.

PMID:
21569999
37.

The histone deacetylase inhibitor sodium butyrate in combination with brain-derived neurotrophic factor reduces the viability of DAOY human medulloblastoma cells.

Nör C, de Farias CB, Abujamra AL, Schwartsmann G, Brunetto AL, Roesler R.

Childs Nerv Syst. 2011 Jun;27(6):897-901. doi: 10.1007/s00381-011-1439-4. Epub 2011 Apr 6.

PMID:
21560052
38.

BDNF/TrkB content and interaction with gastrin-releasing peptide receptor blockade in colorectal cancer.

Brunetto de Farias C, Rosemberg DB, Heinen TE, Koehler-Santos P, Abujamra AL, Kapczinski F, Brunetto AL, Ashton-Prolla P, Meurer L, Reis Bogo M, Damin DC, Schwartsmann G, Roesler R.

Oncology. 2010;79(5-6):430-9. doi: 10.1159/000326564. Epub 2011 Apr 8.

PMID:
21474968
39.

Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies.

Olmos D, Barker D, Sharma R, Brunetto AT, Yap TA, Taegtmeyer AB, Barriuso J, Medani H, Degenhardt YY, Allred AJ, Smith DA, Murray SC, Lampkin TA, Dar MM, Wilson R, de Bono JS, Blagden SP.

Clin Cancer Res. 2011 May 15;17(10):3420-30. doi: 10.1158/1078-0432.CCR-10-2946. Epub 2011 Apr 1.

40.

Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies.

Yap TA, Olmos D, Brunetto AT, Tunariu N, Barriuso J, Riisnaes R, Pope L, Clark J, Futreal A, Germuska M, Collins D, deSouza NM, Leach MO, Savage RE, Waghorne C, Chai F, Garmey E, Schwartz B, Kaye SB, de Bono JS.

J Clin Oncol. 2011 Apr 1;29(10):1271-9. doi: 10.1200/JCO.2010.31.0367. Epub 2011 Mar 7.

PMID:
21383285
41.

Current and emerging molecular targets in glioma.

Roesler R, Brunetto AT, Abujamra AL, de Farias CB, Brunetto AL, Schwartsmann G.

Expert Rev Anticancer Ther. 2010 Nov;10(11):1735-51. doi: 10.1586/era.10.167. Review.

PMID:
21080801
42.

Effects of arm bracing posture on respiratory muscle strength and pulmonary function in patients with chronic obstructive pulmonary disease.

Cavalheri V, Camillo CA, Brunetto AF, Probst VS, Ramos EM, Pitta F.

Rev Port Pneumol. 2010 Nov-Dec;16(6):887-91. English, Portuguese.

43.

Early oncology clinical trial design in the era of molecular-targeted agents.

Brunetto AT, Kristeleit RS, de Bono JS.

Future Oncol. 2010 Aug;6(8):1339-52. doi: 10.2217/fon.10.92. Review.

PMID:
20799878
44.

A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit: unplanned admissions as an early indicator of patient attrition.

Brunetto AT, Ang JE, Olmos D, Tan D, Barriuso J, Arkenau HT, Yap TA, Molife LR, Banerji U, de Bono J, Judson I, Kaye S.

Eur J Cancer. 2010 Oct;46(15):2739-45. doi: 10.1016/j.ejca.2010.06.123. Epub 2010 Aug 11.

PMID:
20667711
45.

Surgical treatment for pediatric mediastinal neurogenic tumors.

Fraga JC, Aydogdu B, Aufieri R, Silva GV, Schopf L, Takamatu E, Brunetto A, Kiely E, Pierro A.

Ann Thorac Surg. 2010 Aug;90(2):413-8. doi: 10.1016/j.athoracsur.2010.04.086.

PMID:
20667322
46.

A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit.

Brunetto AT, Sarker D, Papadatos-Pastos D, Fehrmann R, Kaye SB, Johnston S, Allen M, De Bono JS, Swanton C.

Br J Cancer. 2010 Aug 24;103(5):607-12. doi: 10.1038/sj.bjc.6605812. Epub 2010 Jul 27.

47.

Modest reductions in dose intensity and drug-induced neutropenia have no major impact on survival of patients with non-small cell lung cancer treated with platinum-doublet chemotherapy.

Brunetto AT, Carden CP, Myerson J, Faria AL, Ashley S, Popat S, O'Brien ME.

J Thorac Oncol. 2010 Sep;5(9):1397-403. doi: 10.1097/JTO.0b013e3181eba7f9.

48.

Nutritional status is related to fat-free mass, exercise capacity and inspiratory strength in severe chronic obstructive pulmonary disease patients.

Sabino PG, Silva BM, Brunetto AF.

Clinics (Sao Paulo). 2010 Jun;65(6):599-605. doi: 10.1590/S1807-59322010000600007.

49.

Negative effects of chronic kidney failure on lung function and functional capacity.

Cury JL, Brunetto AF, Aydos RD.

Rev Bras Fisioter. 2010 Mar-Apr;14(2):91-8. Epub 2010 May 14. English, Portuguese.

50.

Recent therapeutic advances for treating medulloblastoma: focus on new molecular targets.

Schmidt AL, Brunetto AL, Schwartsmann G, Roesler R, Abujamra AL.

CNS Neurol Disord Drug Targets. 2010 Jul;9(3):335-48. Review.

PMID:
20438440

Supplemental Content

Loading ...
Support Center